<DOC>
	<DOCNO>NCT00511654</DOCNO>
	<brief_summary>This study conduct obtain information safety tolerability repeat dos GW823296 28 day healthy male female subject . In addition , pharmacokinetics GW823296 evaluate confirm dos use Phase II efficacy study . The effect repeat dose ( RD ) GW823296 CYP3A4 enzyme activity investigate evaluate pharmacokinetics midazolam urine 6- ? -hydroxycortisol/cortisol ratio .</brief_summary>
	<brief_title>28-day Repeat Dose Drug Interaction Study With Orvepitant ( GW823296 )</brief_title>
	<detailed_description />
	<criteria>Healthy determine Physician Responsible , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory variable outside reference range population study , exception liver transaminase , troponin I TSH , may include Investigator considers find introduce additional risk factor interfere study procedure . Please note subject liver transaminase , troponin I TSH value within range specify exclusion criterion . Women nonchildbearing potential ( i.e. , physiologically incapable become pregnant documentation hysterectomy bilateral ovariectomy &gt; 6 month , include female postmenopausal . For purpose study , postmenopausal define one year without menses confirm FSH accord local laboratory range screen ) negative serum hCG pregnancy test screening . No comorbid Psychiatric Disorders define use Mini International Neuropsychiatric Interview ( M.I.N.I ) scale Aged 1865 year , inclusive A 12lead ECG 24hours Holter ECG screening show abnormality opinion Principal Investigator compromise safety study Body weight &gt; 50 kg body mass index ( BMI ) within range 19.029.9 kg/m2 Subjects history peptic ulcer disease ( PUD ) know aetiology must provide documentation gastroenterologist aetiology PUD effective treatment provide full eradication ulcer symptom . For subject appropriate step must also take minimize reoccurrence risk ( i.e . PUD nonsteroidal antiinflammatory drug [ NSAID ] induce , subject longer take NSAID medication ; cause Helicobacter pylorus [ H. pylorus ] , subject appropriately treat ) . For subject , regardless whether positive history PUD , sit require document H. pylorus status screening . Entry study permit subject seropositive H. pylorus , treatment recommend , either study participation discretion Principal Investigator . Capable give write informed consent , include compliance requirement restriction list consent form The subject must able read , comprehend record information . A signed date write informed consent obtain subject . The subject available complete study . The subject screening alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5x upper limit normal range ( ULN ) ; test may repeat see value return within acceptance range laboratory abnormality must resolve baseline visit . Subjects troponin I value &gt; 0.032 ng/mL screen eligible . Testing may repeat . The subject refer treat physician evaluation , appropriate . Subjects TSH value upper limit normal range ( ULN ) screen eligible . The subject refer treat physician evaluation , appropriate . Testing may repeat see whether value return within normal range abnormality must resolve baseline visit . Subjects found stool positive occult blood . If stool obtain without subject abstain red meat 3 day prior test , may repeat follow abstinence . If stool negative occult blood subject consider eligible . Subjects know suspected iron deficiency Subjects history myopathy rhabdomyolysis The subject unable abstain strenuous physical activity 72 hour prior screen , 72 hour prior first dose last PK sample collect , 72 hour prior followup visit . The subject donate unit blood ( 450 mL ) within previous 60 day intend donate month complete study . The subject currently take regular ( course ) medication whether prescribed , include vitamin herbal remedy , St John 's Wort . Any concurrent medication permit 48 hour admission CPRU end study period ( followup visit ) . Typical consumption 14 alcoholic unit week , 3 ( male ) 2 ( female ) alcoholic unit single day , month precede screen visit [ NOTE : 1 unit = 8 oz beer , 3 oz wine , 1 oz hard liquor ] The subject smoke smoke last 3 month . The subject test positive Hepatitis C antibody Hepatitis B surface antigen . The subject test positive HIV1/2 . The subject past history drug abuse test positive urine drug abuse screen . A minimum list drug screen include Amphetamines , Barbiturates , Cocaine , Opiates , Cannabinoids Benzodiazepines . Male subject intend father child study 3 month follow study Subjects history eye disease ( exclude moderate myopia ) clinically relevant eye examination finding , opinion study ophthalmologist contraindicates participation study Vulnerable subject ( e.g . keep detention ) Subjects hypersensitivity intolerance NK1 antagonists Subject know hypersensitivity midazolam one excipients DormicumÂ® ( subject Cohorts 2 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>NK1 receptor antagonist ,</keyword>
	<keyword>depression</keyword>
</DOC>